GSK

Business Context and Reporting Period

This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons, specifically detailing share allocations for Non-Executive Directors.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director compensation in the form of notional share allocations.

Allocations were made at a price of £16.08 per Ordinary Share and $53.75 per ADS for the service period of January 1, 2014, to March 31, 2014.

Material Changes

The filing does not contain comparative financial data or material changes in business operations versus prior periods. It reports a routine administrative allocation of notional shares to Non-Executive Directors.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).

Investor Verification Points

• Verify the total number of notional shares allocated to Non-Executive Directors for the Q1 2014 period.
• Confirm the pricing used for allocations (£16.08 per Ordinary Share and $53.75 per ADS).
• Note that this filing does not contain financial performance results; refer to Form 20-F or quarterly earnings releases for financial metrics.